By addressing these questions, we aim to develop a more practical and accurate multimodal model that can be readily implemented in clinical practice to optimize the selection and monitoring of ICI therapy in non-EGFR/ALK NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.